Saturday 17 October 2026
Export STAA’s income statement to Excel — free account
STAAR Surgical Company
STAA Healthcare Medical Instruments & Supplies
In the quarter to June 2026, revenue grew 111.0%, EPS grew 147.1% and free cash flow grew 166.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
21.27
0.99
−4.45%
Follow STAA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
409.86 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.25 | 3.21 | 4.78 | 5.78 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
73.32 | (43.02) | (292.42) | 500.05 | |
P/B ratio |
3.95 | 2.65 | 3.33 | 3.77 | |
Price to Tangible BV |
3.97 | 2.66 | 3.34 | 3.79 | |
EV/Sales |
3.81 | 2.76 | 4.13 | 4.95 | |
EV/EBITDA |
55.79 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(397.73) | (15.95) | (28.91) | (38.45) | |
EV/FCF |
(189.32) | (14.54) | (24.65) | (28.80) | |
Quick Ratio |
3.81 | 4.02 | 3.47 | 4.10 | |
Current Ratio |
4.66 | 5.12 | 4.55 | 5.21 | |
Net Debt/EBITDA |
(13.53) | (13.33) | 7.54 | (9.46) | |
Debt/Assets |
0.00% | 6.91% | 7.19% | 0.00% | |
Debt/Equity |
0.00 | 0.09 | 0.09 | 0.00 | |
Asset Turnover |
0.74 | 0.64 | 0.50 | 0.46 | |
Operating CF/Net income |
2.44 | (4.17) | 0.21 | 0.30 | |
Capex/Depreciation |
(0.15) | (0.22) | (0.74) | (0.47) | |
Research and Development Expense of Revenue |
10.63% | 10.61% | 15.99% | 9.72% | |
Selling, General and Administrative Expense of Revenue |
53.12% | 44.41% | 78.60% | 46.68% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.01% | 5.16% | 14.90% | 8.61% | |
Graham Net Nets |
0.16 | 0.23 | 0.18 | 0.16 | |
Graham Number |
3.38 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
0.24% | (2.30%) | (7.06%) | (7.26%) | |
Free Cash Flow Yield |
(0.47%) | (5.90%) | (3.51%) | (2.97%) | |
Revenue per Share |
1.86 | 1.87 | 1.17 | 1.91 | |
Operating CF per Share |
0.39 | (0.43) | (0.08) | 0.05 | |
Capex per Share |
(0.01) | (0.01) | (0.03) | (0.02) | |
Free Cash Flow per Share |
0.38 | (0.44) | (0.11) | 0.04 | |
Cash per Share |
3.61 | 3.28 | 3.78 | 3.88 | |
Shareholders Equity per Share |
7.26 | 7.06 | 6.94 | 7.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.26 | 7.06 | 6.94 | 7.13 | |
Free Cash Flow |
19.20 | (22.14) | (5.59) | 1.78 | |
Working Capital |
268.96 | 251.40 | 243.04 | 259.57 | |
Capital Expenditures |
(0.49) | (0.44) | (1.68) | (0.88) | |
Net Current Asset Value |
232.55 | 213.65 | 204.05 | 218.63 | |
EV/EBIT |
94.19 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.03 | 0.01 | |
Price to Operating Income |
105.13 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
66.46 | 60.56 | 63.98 | 82.31 | |
Average Payables |
12.91 | 10.08 | 14.14 | 11.94 | |
Average Inventory |
49.97 | 48.96 | 49.40 | 46.83 | |
Average Assets |
456.49 | 454.24 | 480.60 | 496.98 | |
Average Common Equity |
350.99 | 351.17 | 370.76 | 390.95 |
Columns are period end dates